Radiation drug combined with immunotherapy for extensive-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of a radioactive drug ([225Ac]Ac-DOTATATE) and an immunotherapy drug (Tislelizumab) as maintenance treatment for people with extensive-stage small cell lung cancer (ES-SCLC) whose tumors have a specific protein (SSTR). If you have completed first-line treatment and your cancer shows SSTR on a PET scan, this study may be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 80 years old
- You must have extensive-stage small cell lung cancer that has been confirmed by a biopsy or cell sample
- Your cancer must show SSTR (a protein that the radioactive drug targets) on a PET scan
- You need to have at least one tumor that can be measured on scans
- You must be in good general health (ECOG score 0 or 1) and have adequate organ function (kidney, liver, blood cells)
- You cannot be pregnant or breastfeeding, and must use effective birth control during and for 6 months after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a combination of the immunotherapy drug Adebrelimab plus chemotherapy together with radiation (given at the same time) is better than giving radiation after chemo for people with extensive-stage small cell lung cancer who haven't been treated before.
This study is testing a new combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus standard chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this combination can be more effective than current treatments.
This trial tests a combination of benmelstobart (an immunotherapy drug), anlotinib (a targeted therapy that blocks blood vessel growth), chemotherapy, and chest radiation for people with extensive-stage small cell lung cancer (cancer that has spread beyond one lung). The goal is to see if this combination helps shrink tumors and control the disease better than standard care.
This trial tests a combination of an immunotherapy drug (tislelizumab), chemotherapy, and then radiation to the chest for people with extensive-stage small cell lung cancer who haven't had prior treatment. The goal is to see if this approach helps control the cancer longer.
This trial tests a combination of low-dose radiation to the chest, immunotherapy (adebrelimab), and chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this approach can help control the cancer better than standard treatments and potentially improve outcomes.
This trial tests a new combination of two drugs for people with extensive-stage small cell lung cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
Hear when a new SCLC, Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.